Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
lancastotug (AK127)
i
Other names:
AK127, AK 127, AK-127
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Akesobio
Drug class:
TIGIT inhibitor
Related drugs:
‹
AB154 (5)
BGB-A1217 (5)
RG6058 (3)
HB0030 (1)
EOS-448 (1)
AZD2936 (1)
IBI-939 (1)
MK-7684 (1)
ASP8374 (0)
AUR-106 (0)
BAT6005 (0)
COM902 (0)
DSP502 (0)
HB0036 (0)
HLX-53 (0)
JS006 (0)
MG1131 (0)
PH-804 TME (0)
PM1022 (0)
SEA-TGT (0)
SL-9258 (0)
Undisclosed TIGIT ETB (0)
ZG005 (0)
ZGGS15 (0)
M6223 (0)
MPH-313 (0)
AB308 (0)
BMS-986207 (0)
MK-7684A (0)
AB154 (5)
BGB-A1217 (5)
RG6058 (3)
HB0030 (1)
EOS-448 (1)
AZD2936 (1)
IBI-939 (1)
MK-7684 (1)
ASP8374 (0)
AUR-106 (0)
BAT6005 (0)
COM902 (0)
DSP502 (0)
HB0036 (0)
HLX-53 (0)
JS006 (0)
MG1131 (0)
PH-804 TME (0)
PM1022 (0)
SEA-TGT (0)
SL-9258 (0)
Undisclosed TIGIT ETB (0)
ZG005 (0)
ZGGS15 (0)
M6223 (0)
MPH-313 (0)
AB308 (0)
BMS-986207 (0)
MK-7684A (0)
›
Associations
News
Trials
Filter by
Latest
4ms
A Phase Ib/II Study of AK112 (PD-1/VEGF Bispecific Antibody) in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC). (clinicaltrials.gov)
P1/2, N=280, Not yet recruiting, Akeso
4 months ago
New P1/2 trial • Combination therapy • Metastases
|
Avastin (bevacizumab) • Tyvyt (sintilimab) • Kaitanni (cadonilimab) • Yidafan (ivonescimab) • lancastotug (AK127)
8ms
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov)
P1, N=143, Recruiting, Akesobio Australia Pty Ltd | Phase classification: P1a/1b --> P1
8 months ago
Phase classification • Combination therapy • Metastases
|
Kaitanni (cadonilimab) • lancastotug (AK127)
over1year
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=216, Not yet recruiting, Akeso
over 1 year ago
New P1/2 trial
|
Yidafan (ivonescimab) • lancastotug (AK127)
over1year
A Study of AK127 Combined With AK104 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
P1a/1b, N=205, Not yet recruiting, Akeso
over 1 year ago
New P1 trial • Combination therapy • Metastases
|
Kaitanni (cadonilimab) • lancastotug (AK127)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login